Abstract
Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.
| Original language | English |
|---|---|
| Pages (from-to) | 383-387 |
| Number of pages | 5 |
| Journal | Oncology Research and Treatment |
| Volume | 8 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1985 |
Fingerprint
Keywords
- Chemotherapy
- Ovarian cancer
- RadiationReferences
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
The treatment of ovarian cancer by a multimodality approach : Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation. / Goldhirsch, A.; Greiner, R.; Dreher, E.; Locher, G.; Davis, B. W.; Reinhard, J. P.; Joss, R.; Brunner, K. W.
In: Oncology Research and Treatment, Vol. 8, No. 6, 1985, p. 383-387.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The treatment of ovarian cancer by a multimodality approach
T2 - Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation
AU - Goldhirsch, A.
AU - Greiner, R.
AU - Dreher, E.
AU - Locher, G.
AU - Davis, B. W.
AU - Reinhard, J. P.
AU - Joss, R.
AU - Brunner, K. W.
PY - 1985
Y1 - 1985
N2 - Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.
AB - Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.
KW - Chemotherapy
KW - Ovarian cancer
KW - RadiationReferences
UR - http://www.scopus.com/inward/record.url?scp=0022403323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022403323&partnerID=8YFLogxK
U2 - 10.1159/000215691
DO - 10.1159/000215691
M3 - Article
C2 - 3937969
AN - SCOPUS:0022403323
VL - 8
SP - 383
EP - 387
JO - Oncology Research and Treatment
JF - Oncology Research and Treatment
SN - 2296-5270
IS - 6
ER -